Court Tweaks ANDA Suit Standards, May Widen Declaratory Judgment Window
This article was originally published in The Tan Sheet
The parameters under which generic drug firms can seek declaratory judgments against patent holders could be expanded in a March 30 ruling by the U.S. Court of Appeals for the Federal Circuit
You may also be interested in...
The first application of a recent Supreme Court decision which appears to ease the way for declaratory judgment actions by ANDA filers could come in a case brought by Teva against Novartis regarding Famvir
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning